Lercanidipine

Approved, Investigational Small Molecule

Lercanidipine

Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip. Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.

This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.

Structure

{:NAME:} structure

Summary of Product Characteristics

Field Name Value
NameLercanidipine
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
UNIIV7XTJ4R0BH
CAS number100427-26-7
WeightAverage: 611.7272 Monoisotopic: 611.299536059
Chemical formulaC36H41N3O6
InChI KeyZDXUKAKRHYTAKV-UHFFFAOYSA-N
InChIInChI=1S/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3
IUPAC Name3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SmilesCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
IndicationFor the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
PharmacodynamicsLercanidipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Lercanidipine is similar to other peripheral vasodilators. Lercanidipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Affected organismsHumans and other mammals
Synthesis referenceUS20090227800
Taxonomy descriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super classBenzenoids
ClassBenzene and substituted derivatives
Sub classDiphenylmethanes
Direct parentDiphenylmethanes
Molecular frameworkAromatic heteromonocyclic compounds